View in EDS

1441TiP An open-label, phase Ib trial to assess the safety and efficacy of SIRPα monoclonal antibody BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with head and neck squamous cell carcinoma (NCT06806852)

Saved in:
Bibliographic Details
Title: 1441TiP An open-label, phase Ib trial to assess the safety and efficacy of SIRPα monoclonal antibody BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with head and neck squamous cell carcinoma (NCT06806852)
Authors: Laban, S.1 (AUTHOR), Osinowo, S.2 (AUTHOR), Hu, C.3 (AUTHOR), Tosiek, M.4 (AUTHOR), Pronk, L.C.5 (AUTHOR)
Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS874-S875. 2p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2025.08.2072